MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised
Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.
Why it matters
Attributed market update with source link for portfolio context.